A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer

RECRUITINGPhase 1Sponsored by Memorial Sloan Kettering Cancer Center

Actively Recruiting

PhasePhase 1

SponsorMemorial Sloan Kettering Cancer Center

Started2025-03-03

Est. completion2028-03-03

Eligibility

Age18 Years+

Healthy vol.Accepted

Locations7 sites

View on ClinicalTrials.gov →

NCT06863233

Summary

The purpose of this study to learn whether PET/CT (positron emission tomography/computed tomography) scans using an imaging agent (radiotracer) called zirconium Zr 89 crefmirlimab berdoxam is a safe and effective way to identify CD8+ T cells

Eligibility

Age: 18 Years+Healthy volunteers accepted

Inclusion Criteria:

* Patient must be 18 years of age or older at the time of signing the informed consent.
* Patient has a histologically confirmed diagnosis of metastatic non-small cell lung cancer
* Patient is enrolled in the engineered TIL cell therapy protocol OBX115-23-01, but has not received the treatment yet.
* Men and women of child-producing potential, use of effective double barrier contraceptive methods during the study, up to 30 days after the last administration of the investigational product.
* Patient or legally authorized representative provided signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
* Patient or legally authorized representative provided written authorization for use and disclosure of protected health information.

Exclusion Criteria:

* Pregnant or breastfeeding women
* Patients with a history of splenectomy or significant splenic dysfunction (e.g., as evidenced by splenomegaly or a history of recurrent infections due to impaired immune function)

Conditions4

CancerLung CancerMetastatic Non-Small Cell Lung CancerNon Small Cell Lung Cancer